Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions

Respiratory failure in a 28-year-old male

Danny Wadden, Alvan Buckley, Chandrani Ghosh, Gokul Vidyasankar
Breathe 2020 16: 190337; DOI: 10.1183/20734735.0337-2019
Danny Wadden
1Faculty of Medicine, Memorial University of Newfoundland, St John's, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Danny Wadden
Alvan Buckley
1Faculty of Medicine, Memorial University of Newfoundland, St John's, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chandrani Ghosh
2Memorial University of Newfoundland, St John's, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gokul Vidyasankar
1Faculty of Medicine, Memorial University of Newfoundland, St John's, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gokul.vidyasankar@easternhealth.ca
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

An interesting case of respiratory failure secondary to occupational exposure in a 28-year-old male http://bit.ly/2SzR6dK

A 28-year-old male was admitted to the intensive care unit (ICU) for hypoxic respiratory failure requiring intubation and ventilation. He had been dyspnoeic for months leading up to admission with acute worsening 2 weeks prior and reported a 6-kg weight loss over the same time. Occasional dark sputum was reported without haemoptysis, wheeze, chest pain, fever or infectious symptoms. In regard to social history, he smoked 10 cigarettes per day at the time of presentation (<10-pack-year history) and occasionally used marijuana. He worked as a soapstone carver daily and did not use any respiratory protection. In addition, the patient had exposure to a tuberculosis contact ∼1 year prior to presentation.

On examination, he was noted to be quite thin with decreased breath sounds bilaterally but no adventitious sounds. He was fully ventilated, requiring an inspiratory oxygen fraction between 50% and 85% to maintain saturations. Chest radiography (figure 1) and, subsequently, a high-resolution computed tomography (HRCT) chest were completed (figure 2).

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Posteroanterior chest radiograph of the patient.

Figure 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2

Chest HRCT of the patient.

Task 1

Analyse the chest radiograph.

Answer 1

A diffuse mixed interstitial and airspace nodular pattern with a predominantly perihilar distribution can be seen.

Task 2

Analyse the chest HRCT.

Answer 2

Diffuse alveolar ground-glass opacities are seen with areas of consolidation posteriorly, along with regions of septal thickening.

This patient was started empirically on broad-spectrum antibiotics (piperacillin–tazobactam, 3.375 g every 6 h, and trimethoprim/sulfame­thoxazole, two double-strength tablets three times a day) to cover potential infectious aetiologies. Due to severe hypoxaemia, a trial of high-dose (500 mg·day−1 methylprednisolone) pulse corticosteroids was also given, without clinical improvement.

Task 3

What is your differential diagnosis?

Answer 3

The differential diagnosis at the present time included infectious aetiologies (bacterial, mycobacterial, viral or fungal), acute hypersensitivity pneumonitis, pulmonary alveolar proteinosis, sarcoidosis and occupational lung injury.

Task 4

What is the next most appropriate diagnosis step?

  1. Bronchoscopy

  2. Repeat HRCT with inspiratory and expiratory views

  3. Lung biopsy

  4. Positron emission tomography scan

Answer 4

a. Bronchoscopy

Bronchoscopy was completed showing mild inflammation diffusely with dense mucous plugging in the lower lobes and no evidence of haemorrhage. Bronchial toileting was performed and copious amounts of dark mucous was cleared. Washings were sent for extensive microbiology testing (viruses, bacteriology, and fungal and mycobacterial cultures) and cytology. All infectious workup returned negative. Cytological analysis showed:

  • abundant amorphous and finely granular proteinaceous material, scattered macrophages, degenerated epithelial cells and few groups of cells with regenerative atypia

  • scattered birefringent material noted under polarised microscopy consistent with silicates

  • periodic acid–Schiff (PAS) and PAS–diastase positive staining (figure 3)

Figure 3
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3

Cytology from bronchoalveolar lavage showing: a) surfactant material lipoprotein material within the alveoli; b) positive PAS stain; and c) positive PAS–diastase stain.

Task 5

What is the most likely diagnosis?

Answer 5

The most likely diagnosis is acute silicoproteinosis from occupational exposure.

The overall clinical picture was suggestive of acute silicoproteinosis. At this point, it was decided to proceed with whole-lung lavage. The thoracic surgery department was consulted, with the cardiovascular surgery department on standby in case extracorporeal membrane oxygenation (ECMO) was needed. The patient was brought to the operating room and his left lung was lavaged with a total of 22 L normal saline. The returning fluid was dark and turbid in appearance (figure 4) but progressively cleared with each irrigation. The patient remained haemodynamically stable throughout the procedure, and was transferred back to the ICU intubated and ventilated. He was extubated the following day to 40% high-flow oxygen.

Figure 4
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4

Returning whole-lung lavage fluid showing clearance of sediment.

A follow-up HRCT chest was completed 4 days post-whole lung lavage, which showed some improvement in his airspace disease, with increased dependent consolidations that were felt to be related to retained lavage fluid. Recovery was gradual and by post-procedure day 17, he required 6 L oxygen via nasal cannula. At this point, it was decided to proceed with lavage of the right lung, which was completed with 20 L normal saline. Once again, the patient tolerated the procedure extremely well. Recovery was more rapid thereafter and over the next few days, he was weaned to room air and discharged home in stable condition. Follow up HRCT of the chest 6 months later showed a marked improvement in airspace disease, with residual centrilobular ground-glass nodules (figure 5).

Figure 5
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5

Repeat HRCT imaging 5 months from admission showing resolution of pulmonary infiltrates.

Discussion

Occupational and environmental lung diseases represent a vast spectrum of respiratory pathologies [1]. Exposure to silica from various industrial activities has been associated with silicosis [2]. Silicosis is further divided into chronic and accelerated silicosis, and silicoproteinosis. Chronic silicosis and accelerated silicosis occur 10 years and 5–10 years after exposure, respectively [2, 3]. Acute silicoproteinosis occurs weeks to 5 years after exposure to large quantities of silica and is similar to pulmonary alveolar proteinosis (PAP), with alveolar deposition of lipoproteinaceous material, positive for PAS stain [4]. Current literature divides PAP into three groups: autoimmune, secondary and genetic [5], with autoimmune PAP accounting for ∼90% of cases [6]. Silica exposure falls under a secondary (toxic inhalation) cause of PAP. Granulocyte–macrophage colony-stimulating factor (GM-CSF) has been shown to be important in some forms of PAP [7] as antibodies to GM-CSF resulted in dysfunction of alveolar macrophages influencing surfactant clearance [8]. On HRCT, the “crazy paving” pattern of ground-glass opacities and interlobular septal thickening is often seen in PAP [9]. Bronchoalveolar lavage in PAP may have a characteristic “milky” appearance due to the surfactant material within the alveoli and the fluid should generally stain positive for PAS [10]. Whole-lung lavage remains the cornerstone of treatment of PAP [11] and has recently been reviewed by Gay et al. [12], though GM-CSF replacement [13], immunomodulatory therapy [14] and plasmapheresis [15] have been explored.

Regarding acute silicoproteinosis and whole-lung lavage, few case reports are available to guide treatment. Moreira et al. [16] described a case of secondary PAP in a 44-year-old male who had a significant exposure to silica, and a past history of both silicosis and treated pulmonary tuberculosis, presenting with hypoxaemic respiratory failure on the background of 4 months of dyspnoea on exertion. The patient was supported on venovenous ECMO and bilateral whole-lung lavage was completed, with favourable outcomes and an improvement in hypoxaemia. Huaringa et al. [17] described a case of a 52-year-old male with significant occupational exposure to silica, without use of personal protective equipment. He presented with exertional dyspnoea over 1.5 years, with a cough productive of white sputum. Chest imaging showed bilateral infiltrates, and biopsies via bronchoscope revealed refringent particles (silica) and PAS-positive lipoproteinaceous material. The patient underwent whole-lung lavage (double-lumen endotracheal tube; dependent lung down) with ∼20 L. 1 week later, the second lung was lavaged. Overall, there was significant improvement in symptoms and oxygenation [17]. Stafford et al. [18] described a case most similar to ours. Their patient was a 32-year-old male presenting with a 9-month history of dyspnoea, cough and fever. He had significant occupational exposure to silica. Through imaging and bronchoscopic evaluation, he was diagnosed with acute silicoproteinosis. Pathology from bronchoscopy showed birefringent crystals compatible with silica. He was originally treated with methylprednisone for 3 days with mild improvement, and discharged on supplemental oxygen and corticosteroid taper. He re-presented with worsening hypoxaemia. Whole-lung lavage was then completed first in the right lung, followed by the left lung 4 days later. The lavage return was cloudy, and 20 and 30 L were irrigated in the right and left lung, respectively. The patient was able to be weaned to his baseline oxygen requirements of 4 L·min−1 [18].

Crystalline silica dust exposure remains a significant occupational hazard globally, with a spectrum of disease ranging from chronic fibrosis to acute silicoproteinosis, the latter of which can cause hypoxaemic respiratory failure. From our clinical case and the small number of case reports in the literature, it is evident that whole-lung lavage may be a viable treatment option for secondary PAP due to silica inhalation. Large-volume lavage is likely required and subsequent recovery may be gradual. Ongoing research is needed in this field.

Footnotes

  • Conflict of interest: D. Wadden has nothing to disclose.

  • Conflict of interest: A. Buckley has nothing to disclose.

  • Conflict of interest: C. Ghosh has no conflict of interest.

  • Conflict of interest: G. Vidyasankar has nothing to disclose.

  • Copyright ©ERS 2020
http://creativecommons.org/licenses/by-nc/4.0/

Breathe articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Moitra S,
    2. Puri R,
    3. Paul D, et al.
    Global perspectives of emerging occupational and environmental lung diseases. Curr Opin Pulm Med 2015; 21: 114–120. doi:10.1097/MCP.0000000000000136
    OpenUrl
  2. ↵
    1. Leung CC,
    2. Yu IT,
    3. Chen W
    . Silicosis. Lancet 2012; 379: 2008–2018. doi:10.1016/S0140-6736(12)60235-9
    OpenUrlCrossRefPubMed
  3. ↵
    1. Greenberg MI,
    2. Waksman J,
    3. Curtis J
    . Silicosis: a review. Dis Mon 2007; 53: 394–416. doi:10.1016/j.disamonth.2007.09.020
    OpenUrlCrossRefPubMed
  4. ↵
    1. Buechner HA,
    2. Ansari A
    . Acute silico-proteinosis. A new pathologic variant of acute silicosis in sandblasters, characterized by histologic features resembling alveolar proteinosis. Dis Chest 1969; 55: 274–278. doi:10.1378/chest.55.4.274
    OpenUrlCrossRefPubMed
  5. ↵
    1. Borie R,
    2. Danel C,
    3. Debray MP, et al.
    Pulmonary alveolar proteinosis. Eur Respir Rev 2011; 20: 98–107. doi:10.1183/09059180.00001311
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Inoue Y,
    2. Trapnell BC,
    3. Tazawa R, et al.
    Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med 2008; 177: 752–762. doi:10.1164/rccm.200708-1271OC
    OpenUrlCrossRefPubMed
  7. ↵
    1. Antoniu SA
    . GM-CSF pathway correction in pulmonary alveolar proteinosis. Expert Opin Biol Ther 2010; 10: 1357–1365. doi:10.1517/14712598.2010.510507
    OpenUrlCrossRefPubMed
  8. ↵
    1. Kitamura T,
    2. Tanaka N,
    3. Watanabe J, et al.
    Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med 1999; 190: 875–880. doi:10.1084/jem.190.6.875
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Ben-Dov I,
    2. Segel MJ
    . Autoimmune pulmonary alveolar proteinosis: clinical course and diagnostic criteria. Autoimmun Rev 2014; 13: 513–517. doi:10.1016/j.autrev.2014.01.046
    OpenUrlCrossRefPubMed
  10. ↵
    1. Milleron BJ,
    2. Costabel U,
    3. Teschler H, et al.
    Bronchoalveolar lavage cell data in alveolar proteinosis. Am Rev Respir Dis 1991; 144: 1330–1332. doi:10.1164/ajrccm/144.6.1330
    OpenUrlPubMed
  11. ↵
    1. Michaud G,
    2. Reddy C,
    3. Ernst A
    . Whole-lung lavage for pulmonary alveolar proteinosis. Chest 2009; 136: 1678–1681. doi:10.1378/chest.09-2295
    OpenUrlCrossRefPubMed
  12. ↵
    1. Gay P,
    2. Wallaert B,
    3. Nowak S, et al.
    Efficacy of whole-lung lavage in pulmonary alveolar proteinosis: a multicenter international study of GELF. Respiration 2017; 93: 198–206. doi:10.1159/000455179
    OpenUrl
  13. ↵
    1. Seymour JF,
    2. Presneill JJ,
    3. Schoch OD, et al.
    Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis. Am J Respir Crit Care Med 2001; 163: 524–531. doi:10.1164/ajrccm.163.2.2003146
    OpenUrlPubMed
  14. ↵
    1. Kavuru MS,
    2. Malur A,
    3. Marshall I, et al.
    An open-label trial of rituximab therapy in pulmonary alveolar proteinosis. Eur Respir J 2011; 38: 1361–1367. doi:10.1183/09031936.00197710
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Luisetti M,
    2. Rodi G,
    3. Perotti C, et al.
    Plasmapheresis for treatment of pulmonary alveolar proteinosis. Eur Respir J 2009; 33: 1220–1222. doi:10.1183/09031936.00097508
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Moreira JP,
    2. Ferraz S,
    3. Freitas C, et al.
    Whole-lung lavage for severe pulmonary alveolar proteinosis assisted by veno-venous extracorporeal membrane oxygenation: a case report. Can J Respir Ther 2018; 55: 9–12.
    OpenUrl
  17. ↵
    1. Huaringa AJ,
    2. Francis WH
    . Pulmonary alveolar proteinosis: a case report and world literature review. Respirol Case Rep 2016; 4: e00201.
    OpenUrl
  18. ↵
    1. Stafford M,
    2. Cappa A,
    3. Weyant M, et al.
    Treatment of acute silicoproteinosis by whole-lung lavage. Semin Cardiothorac Vasc Anesth 2013; 17: 152–159. doi:10.1177/1089253213486524
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Vol 16 Issue 2 Table of Contents
Breathe: 16 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Respiratory failure in a 28-year-old male
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Respiratory failure in a 28-year-old male
Danny Wadden, Alvan Buckley, Chandrani Ghosh, Gokul Vidyasankar
Breathe Jun 2020, 16 (2) 190337; DOI: 10.1183/20734735.0337-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Respiratory failure in a 28-year-old male
Danny Wadden, Alvan Buckley, Chandrani Ghosh, Gokul Vidyasankar
Breathe Jun 2020, 16 (2) 190337; DOI: 10.1183/20734735.0337-2019
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Expert opinion

  • Lung cancer screening by volume CT
  • In pursuit of the primary
  • A rare complication in a case of nonsmall cell lung carcinoma
Show more Expert opinion

Case reports

  • An unusual progressive stridor
  • A difficult pleural effusion in a cirrhotic patient
  • The perils of a persistent cough
Show more Case reports

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About Breathe

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Intructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 1810-6838
Online ISSN: 2073-4735

Copyright © 2022 by the European Respiratory Society